The role of IgG4 in the pathogenesis of IgG4-related disease remains unclear, particularly regarding whether IgG4 actively induces histopathological changes or if its elevation is merely a byproduct ...

Andrew Kuykendall, MD, discusses data from a phase 2 trial of fedratinib for the treatment of myeloproliferative neoplasms.

BeiGene aims to be a next-generation oncology innovator by broadening its drug and pipeline portfolio to various solid tumors in addition to blood cancers. As such, it been actively investing to build ...

A next-generation "armored" CAR T cell therapy showed promising results in a small study of patients whose B-cell lymphomas ...

Pediatric patients with high-risk neuroblastoma had significantly lower 5-year survival rates in induction and/or ...

Iron deficiency—when there's too little iron in the blood—may affect a quarter of the world's population, and in particular, women of reproductive age. Symptoms can include fatigue and shortness of ...

A next-generation "armored" CAR T cell therapy showed promising results in a small study of patients whose B-cell lymphomas continued to resist multiple rounds of other cancer treatments, including ...

UnityPoint Health celebrated the expansion of the Cancer Center in Moline. The work renovated more than 10,000 square feet of space. The updates include installing more infusion chairs, adding new ...

Amandeep Salhotra, MD, discusses data from the phase 3 Precision-T trial of Orca-T in patients with advanced hematologic malignancies.

The use of GLP-1s among patients with type 2 diabetes appeared associated with significantly reduced risk for certain ...

A 77-year-old woman was admitted to Matsunami General Hospital (Gifu, Japan) with anaemia and thrombocytopenia. Clinical laboratory data showed a white blood cell count of 4300 per μL (normal range ...

Over 80% of patients with relapsed/refractory multiple myeloma responded to anti-GPRC5D CAR T-cell therapy after failure of anti-BCMA CAR T-cell therapy. The investigational therapy showed ...